MedTrace Logo

T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma

NCT01946373 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-10-04

No results posted yet for this study

Summary

The purpose of this study is to learn if dendritic cell vaccine will increase the effect of tumor infiltrating lymphocytes given with chemotherapy and interleukin-2 in patients with melanoma.

Conditions

Interventions

DRUG

Cyclophosphamide

DRUG

Fludarabine

BIOLOGICAL

T cells

BIOLOGICAL

Interleukin-2

BIOLOGICAL

Dendritic cell vaccine

Sponsors & Collaborators

  • Karolinska University Hospital

    lead OTHER

Principal Investigators

  • Maria Wolodarski, MD · Karolinska University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01946373 on ClinicalTrials.gov